On November 19, 2021 Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics (EPBs), reported the publication of two abstract poster presentations to be conducted at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is being held from December 7-10, 2021 (Press release, Ambrx, NOV 19, 2021, View Source [SID1234595858]). The abstract poster presentations will highlight clinical data from Ambrx’s ongoing ACE-Breast-03 and ACE-Breast-01 clinical trials of ARX788. The company’s ACE-Breast-01 abstract was selected as a Spotlight Poster Discussion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All posters will be available virtually on the SABCS website at www.SABCS.org as well as in the symposium poster hall beginning Wednesday, December 8, 2021 at 9:00 AM ET. Details on the abstracts and corresponding poster presentations are shown below.

Poster Number: OT1-02-02
Title: "A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens"
Presentation Time: December 8, 2021 at 5:00 PM CST
Session Name: Ongoing Trials Poster Session 1
Presenters: Sara Hurvitz, MD; Janice Lu, MD; Joy Yan, MD, PhD

Spotlight Poster Discussion Number: PD8-04
Poster Title: "Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents (trastuzumab, ADCs, TKIs, and bispecific antibodies): ACE-Breast-01 trial results"
Presentation Time: December 9, 2021 at 7:00 AM CST
Session Name: Spotlight Poster Discussion 8
Presenters: Xichun Hu, MD; Jiang Zhang, MD